Year: 2026
Type: review
Abstract: Liver involvement in ovarian cancer is often treated as a single clinical entity, although liver-surface implants and parenchymal deposits occupy different anatomical settings and may not share the same molecular history. Primary-tumor profiling is informative, but can miss lesion-specific evolution, treatment-associated cell states, and microenvironmental structure. This Mini Review examines how germline susceptibility, somatic change, spatial biology, and artificial intelligence might be combined in high-grade serous ovarian cancer. The central task is not simply outcome prediction. It is to distinguish constitutional from tumor-acquired variation, retain lesion identity and treatment timing, and relate molecular programs to defined spatial compartments. Current data support marked clonal and microenvironmental heterogeneity in ovarian cancer, but direct molecular evidence from hepatic lesions remains sparse. AI-based integration is therefore best viewed as a way to formulate and test reproducible hypotheses, rather than as a validated route to select liver-directed therapy. Paired sampling, orthogonal assays, patient-level validation, and decision-specific clinical endpoints will be needed before these models can influence management.
Source: Frontiers in Genetics
Authors: Louxun Sun, Zhongshan Li, Shiming Chen
Institution: Shaoxing Second Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7222976243